Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Meral Beksac, Hang Quach, Vania Hungria, Luděk Pour, Kihyun Kim, Sergey Voloshin, Hanlon Sia, Esther Gonzalez, Chang-Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda, Ivan Spicka, Marek Hus, Vera Zherebtsova, Margaret Polinkovsky, Sybil Varghese, Joe Lee, Elisabet Manasanch, Pawel Robak, Meletios Athanasios Dimopoulos
Institutions: Istinye University, Liv Hospital, The University of Melbourne, St Vincent's Hospital Melbourne, São Germano Oncologia, University Hospital Brno, Samsung Medical Center, Sungkyunkwan University, Russian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency, Hospital Universitario De Cabueñes, St. Paul's Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Universidade da Região de Joinville, Duran i Reynals Hospital, Charles University, General University Hospital in Prague, Medical University of Lublin, Botkin Hospital, GlaxoSmithKline (United States), GlaxoSmithKline Research & Development Limited (United Kingdom), National and Kapodistrian University of Athens
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410809738